Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases

Archives of Pharmacal Research

Volumn 36, Issue 9, 2013, Pages 1039-1050

  Bose, Shambhunath ^a   Cho, Jungsook ^a  

^a Dongguk University   (South Korea)

Author keywords

CCL2; CCR2; G protein coupled receptor; Neurodegenerative diseases

Indexed keywords

BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1;

ALZHEIMER DISEASE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CHEMOTAXIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFLAMMATION; LEUKOCYTE MIGRATION; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CHEMOKINE CCL2; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; NOOTROPIC AGENTS; RECEPTORS, CCR2; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84884208321     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0161-z     Document Type: Review

References (79)

1. Andjelkovic, A.V.; L. Song, K.A. Dzenko, H. Cong, and J.S. Pachter. 2002. Functional expression of CCR2 by human fetal astrocytes. The Journal of Neuroscience Research 70: 219-231.
2. Arakelyan, A.; J. Petrkova, Z. Hermanova, A. Boyajyan, J. Lukl, and M. Petrek. 2005. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators of Inflammation 3: 175-179.
3. Bacon, K.; M. Baggiolini, H. Broxmeyer, R. Horuk, I. Lindley, A. Mantovani, K. Maysushima, P. Murphy, H. Nomiyama, J. Oppenheim, A. Rot, T. Schall, M. Tsang, R. Thorpe, J. Van Damme, M. Wadhwa, O. Yoshie, A. Zlotnik, and K. Zoon. 2002. Chemokine/chemokine receptor nomenclature. The Journal of Interferon and Cytokine Research 22: 1067-1068.
4. Bajetto, A.; R. Bonavia, S. Barbero, T. Florio, and G. Schettini. 2001. Chemokines and their receptors in the central nervous system. Frontiers in Neuroendocrinology 22: 147-184.
5. Banisadr, G.; R.D. Gosselin, P. Mechighel, P. Kitabgi, W. Rostène, and S.M. Parsadaniantz. 2005a. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. The Journal of Comparative Neurology 489: 275-292.
6. Banisadr, G.; R.D. Gosselin, P. Mechighel, W. Rostène, P. Kitabgi, and S. Mélik Parsadaniantz. 2005b. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. The Journal of Comparative Neurology 492: 178-192.
7. Beall, C.J.; S. Mahajan, D.E. Kuhn, and P.E. Kolattukudy. 1996. Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity. Biochemical Journal 313: 633-640.
8. Boddeke, E.W.; I. Meigel, S. Frentzel, N.G. Gourmala, J.K. Harrison, M. Buttini, O. Spleiss, and P. Gebicke-Härter. 1999. Cultured rat microglia express functional beta-chemokine receptors. The Journal of Neuroimmunology 98: 176-184.
9. Bonecchi, R.; E. Galliera, E.M. Borroni, M.M. Corsi, M. Locati, and A. Mantovani. 2009. Chemokines and chemokine receptors: an overview. Frontiers in Bioscience 14: 540-551.
10. Brosnan, C.F.; and C.S. Raine. 1996. Mechanisms of immune injury in multiple sclerosis. Brain Pathology 6: 243-257.
11. Charo, I.F.; S.J. Myers, A. Herman, C. Franci, A.J. Connolly, and S.R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proceedings of the National Academy of Sciences of the United States of America 91: 2752-2756.
12. Che, X.; W. Ye, L. Panga, D.C. Wu, and G.Y. Yang. 2001. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Research 902: 171-177.
13. Chen, Y.; J.M. Hallenbeck, C. Ruetzler, D. Bol, K. Thomas, N.E. Berman, and S.N. Vogel. 2003. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. The Journal of Cerebral Blood Flow and Metabolism 23: 748-755.
14. Cho, J.; and D.L. Gruol. 2008. The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells. The Journal of Neuroimmunology 199: 94-103.
15. Conductier, G.; N. Blondeau, A. Guyon, J.L. Nahon, and C. Rovère. 2010. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. The Journal of Neuroimmunology 224: 93-100.
16. Dawson, J.; W. Miltz, A.K. Mir, and C. Wiessner. 2003. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opinion on Therapeutic Targets 7: 35-48.
17. Deshmane, S.L.; S. Kremlev, S. Amini, and B.E. Sawaya. 2009. Monocyte chemoattractant protein-1 (MCP-1): an overview. The Journal of Interferon and Cytokine Research 29: 313-326.
18. Dimitrijevic, O.B.; S.M. Stamatovic, R.F. Keep, and A.V. Andjelkovic. 2007. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 38: 1345-1353.
19. Dirnagl, U.; C. Iadecola, and M.A. Moskowitz. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends in Neurosciences 22: 391-397.
20. Ebisawa, M.; T. Yamada, C. Bickel, D. Klunk, and R.P. Schleimer. 1994. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. The Journal of Immunology 153: 2153-2160.
21. Esiri, M.M. 2007. The interplay between inflammation and neurodegeneration in CNS disease. The Journal of Neuroimmunology 184: 4-16.
22. Fuentes, M.E.; S.K. Durham, M.R. Swerdel, A.C. Lewin, D.S. Barton, J.R. Megill, R. Bravo, and S.A. Lira. 1995. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. The Journal of Immunology 155: 5769-5776.
23. Galimberti, D.; C. Fenoglio, C. Lovati, E. Venturelli, I. Guidi, B. Corrà, D. Scalabrini, F. Clerici, C. Mariani, N. Bresolin, and E. Scarpini. 2006. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiology of Aging 27: 1763-1768.
24. Gao, Y.J.; and R.R. Ji. 2010. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacology and Therapeutics 126: 56-68.
25. Gerard, C.; and B.J. Rollins. 2001. Chemokines and disease. Nature Immunology 2: 108-115.
26. Glabinski, A.R.; V. Balasingam, M. Tani, S.L. Kunkel, R.M. Strieter, V.W. Yong, and R.M. Ransohoff. 1996. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. The Journal of Immunology 156: 4363-4368.
27. Goncharova, L.B.; and A.O. Tarakanov. 2008. Why chemokines are cytokines while their receptors are not cytokine ones? Current Medicinal Chemistry 15: 1297-1304.
28. Gong, J.H.; L.G. Ratkay, J.D. Waterfield, and I. Clark-Lewis. 1997. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. The Journal of Experimental Medicine 186: 131-137.
29. Gosselin, R.D.; C. Varela, G. Banisadr, P. Mechighel, W. Rostene, P. Kitabgi, and S. Melik-Parsadaniantz. 2005. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. The Journal of Neurochemistry 95: 1023-1034.
30. Gourmala, N.G.; M. Buttini, S. Limonta, A. Sauter, and H.W. Boddeke. 1997. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. The Journal of Neuroimmunology 74: 35-44.
31. Gouwy, M.; S. Struyf, J. Catusse, P. Proost, and J. Van Damme. 2004. Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. The Journal of Leukocyte Biology 76: 185-194.
32. Horuk, R. 2001. Chemokine receptors. Cytokine and Growth Factor Reviews 12: 313-335.
33. Horuk, R. 2009. Chemokine receptor antagonists: overcoming developmental hurdles. Nature reviews Drug discovery 8: 23-33.
34. Huang, D.; M. Tani, J. Wang, Y. Han, T.T. He, J. Weaver, I.F. Charo, V.K. Tuohy, B.J. Rollins, and R.M. Ransohoff. 2002. Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. The Journal of Neuroscience 22: 10633-10642.
35. Huang, D.; J. Wujek, G. Kidd, T.T. He, A. Cardona, M.E. Sasse, E.J. Stein, J. Kish, M. Tani, I.F. Charo, A.E. Proudfoot, B.J. Rollins, T. Handel, and R.M. Ransohoff. 2005. Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. The FASEB Journal 19: 761-772.
36. Hughes, P.M.; P.R. Allegrini, M. Rudin, V.H. Perry, A.K. Mir, and C. Wiessner. 2002. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. The Journal of Cerebral Blood Flow and Metabolism 22: 308-317.
37. Hulkower, K.; C.F. Brosnan, D.A. Aquino, W. Cammer, S. Kulshrestha, M.P. Guida, D.A. Rapoport, and J.W. Berman. 1993. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. The Journal of Immunology 150: 2525-2533.
38. Ishizuka, K.; T. Kimura, R. Igata-yi, S. Katsuragi, J. Takamatsu, and T. Miyakawa. 1997. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry and Clinical Neurosciences 51: 135-138.
39. Izikson, L.; R.S. Klein, I.F. Charo, H.L. Weiner, and A.D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. The Journal of Experimental Medicine 192: 1075-1080.
40. Karpus, W.J.; and R.M. Ransohoff. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. The Journal of Immunology 161: 2667-2671.
41. Kim, J.S.; S.C. Gautam, M. Chopp, C. Zaloga, M.L. Jones, P.A. Ward, and K.M. Welch. 1995. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. The Journal of Neuroimmunology 56: 127-134.
42. Kiyota, T.; M. Yamamoto, H. Xiong, M.P. Lambert, W.L. Klein, H.E. Gendelman, R.M. Ransohoff, and T. Ikezu. 2009. CCL2 accelerates microglia-mediated Aβ oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4: e6197.
43. Kothandan, G.; C.G. Gadhe, and S.J. Cho. 2012. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study. PLoS ONE 7: e32864.
44. Kuang, Y.; Y. Wu, H. Jiang, and D. Wu. 1996. Selective G protein coupling by C-C chemokine receptors. The Journal of Biological Chemistry 271: 3975-3978.
45. Kumai, Y.; H. Ooboshi, J. Takada, M. Kamouchi, T. Kitazono, K. Egashira, S. Ibayashi, and M. Iida. 2004. Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats. The Journal of Cerebral Blood Flow and Metabolism 24: 1359-1368.
46. Lau, E.K.; C.D. Paavola, Z. Johnson, J.P. Gaudry, E. Geretti, F. Borlat, A.J. Kungl, A.E. Proudfoot, and T.M. Handel. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. The Journal of Biological Chemistry 279: 22294-22305.
47. Lee, Y.J.; S.B. Han, S.Y. Nam, K.W. Oh, and J.T. Hong. 2010. Inflammation and Alzheimer's disease. Archives of Pharmacal Research 33: 1539-1556.
48. Locati, M.; G. Lamorte, W. Luini, M. Introna, S. Bernasconi, A. Mantovani, and S. Sozzani. 1996. Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. The Journal of Biological Chemistry 271: 6010-6016.
49. Losy, J.; and J. Zaremba. 2001. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 32: 2695-2696.
50. Lucchinetti, C.F.; W. Brück, M. Rodriguez, and H. Lassmann. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathology 6: 259-274.
51. Mahad, D.J.; and R.M. Ransohoff. 2003. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Seminars in Immunology 15: 23-32.
52. McManus, C.; J.W. Berman, F.M. Brett, H. Staunton, M. Farrell, and C.F. Brosnan. 1998. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. The Journal of Neuroimmunology 86: 20-29.
53. Mirabelli-Badenier, M.; V. Braunersreuther, G.L. Viviani, F. Dallegri, A. Quercioli, E. Veneselli, F. Mach, and F. Montecucco. 2011. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thrombosis and Haemostasis 105: 409-420.
54. Monteclaro, F.S.; and I.F. Charo. 1996. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. The Journal of Biological Chemistry 271: 19084-19092.
55. Monteclaro, F.S.; and I.F. Charo. 1997. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. The Journal of Biological Chemistry 272: 23186-23190.
56. Moreaux, J. 2010. CCR2 (chemokine (C-C motif) receptor 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology 14: 938-941.
57. Old, E.A.; and M. Malcangio. 2012. Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. Current Opinion in Pharmacology 12: 67-73.
58. Proudfoot, A.E.; C.A. Power, and M.K. Schwarz. 2010. Anti-chemokine small molecule drugs: a promising future? Expert Opinion on Investigational Drugs 19: 345-355.
59. Ransohoff, R.M.; T.A. Hamilton, M. Tani, M.H. Stoler, H.E. Shick, J.A. Major, M.L. Estes, D.M. Thomas, and V.K. Tuohy. 1993. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. The FASEB Journal 7: 592-600.
60. Ransohoff, R.M. 2002. The chemokine system in neuroinflammation: an update. The Journal of Infectious Diseases 186(Suppl 2): S152-S156.
61. Rollins, B.J. 1991. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells 3: 517-524.
62. Rollins, B.J. 1996. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Molecular Medicine Today 2: 198-204.
63. Rollins, B.J. 1997. Chemokines. Blood 90: 909-928.
64. Rostène, W.; P. Kitabgi, and S.M. Parsadaniantz. 2007. Chemokines: a new class of neuromodulator? Nature Reviews Neuroscience 8: 895-903.
65. Semple, B.D.; T. Kossmann, and M.C. Morganti-Kossmann. 2010. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. The Journal of Cerebral Blood Flow and Metabolism 30: 459-473.
66. Simpson, J.E.; J. Newcombe, M.L. Cuzner, and M.N. Woodroofe. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. The Journal of Neuroimmunology 84: 238-249.
67. Simpson, J.; P. Rezaie, J. Newcombe, M.L. Cuzner, D. Male, and M.N. Woodroofe. 2000. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. The Journal of Neuroimmunology 108: 192-200.
68. Sozzani, S.; D. Zhou, M. Locati, M. Rieppi, P. Proost, M. Magazin, N. Vita, J. van Damme, and A. Mantovani. 1994. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. The Journal of Immunology 152: 3615-3622.
69. Terashima, Y.; N. Onai, M. Murai, M. Enomoto, V. Poonpiriya, T. Hamada, K. Motomura, M. Suwa, T. Ezaki, T. Haga, S. Kanegasaki, and K. Matsushima. 2005. Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis. Nature Immunology 6: 827-835.
70. Thathiah, A.; and B. De Strooper. 2011. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nature Reviews Neuroscience 12: 73-87.
71. Tran, E.H.; K. Hoekstra, N. van Rooijen, C.D. Dijkstra, and T. Owens. 1998. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. The Journal of Immunology 161: 3767-3775.
72. Van Coillie, E.; J. Van Damme, and G. Opdenakker. 1999. The MCP/eotaxin subfamily of CC chemokines. Cytokine and Growth Factor Reviews 10: 61-86.
73. Wain, J.H.; J.A. Kirby, and S. Ali. 2002. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. Clinical and Experimental Immunology 127: 436-444.
74. Wang, X.; and G.Z. Feuerstein. 1995. Induced expression of adhesion molecules following focal brain ischemia. The Journal of Neurotrauma 12: 825-832.
75. Xia, M.; and Z. Sui. 2009. Recent developments in CCR2 antagonists. Expert Opinion on Therapeutic Patents 19: 295-303.
76. Yamamoto, M.; M. Horiba, J.L. Buescher, D. Huang, H.E. Gendelman, R.M. Ransohoff, and T. Ikezu. 2005. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. American Journal of Pathology 166: 1475-1485.
77. Yamasaki, R.; L. Liu, J. Lin, and R.M. Ransohoff. 2012. Role of CCR2 in immunobiology and neurobiology. Clinical and Experimental Neuroimmunology 3: 16-29.
78. Youssef, S.; G. Wildbaum, G. Maor, N. Lanir, A. Gour-Lavie, N. Grabie, and N. Karin. 1998. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. The Journal of Immunology 161: 3870-3879.
79. Zhang, Y.; and B.J. Rollins. 1995. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Molecular and Cellular Biology 15: 4851-4855.